...
首页> 外文期刊>Frontiers in Cell and Developmental Biology >Use of Acid Ceramidase and Sphingosine Kinase Inhibitors as Antiviral Compounds Against Measles Virus Infection of Lymphocytes in vitro
【24h】

Use of Acid Ceramidase and Sphingosine Kinase Inhibitors as Antiviral Compounds Against Measles Virus Infection of Lymphocytes in vitro

机译:酸性神经酰胺酶和鞘氨醇激酶抑制剂作为抗麻疹病毒感染淋巴细胞的体外抗病毒化合物的用途

获取原文
           

摘要

As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses. Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication. Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70-80% in BJAB cells. Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides. SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells. Furthermore, we found that MV infection of lymphocytes induce a transient (0.5 to 6 h) increase in S1P, which was prevented by SKI-II. Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells. As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism. In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication. Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL. Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and sphingosine kinase inhibitors impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus.
机译:鞘脂作为结构膜成分和信号传导效应分子会影响宿主细胞的多种功能,因此也会复制病毒。研究各种鞘脂代谢抑制剂在人类原代外周血淋巴细胞(PBL)和人类B细胞系BJAB中的作用,我们发现不仅鞘氨醇激酶(SphK)抑制剂SKI-II,而且酸性神经酰胺酶抑制剂ceranib-2有效抑制麻疹病毒(MV)复制。两种抑制剂并未完全改变病毒对靶细胞的吸收,而新合成的MV的滴度在PBL中降低了约1 log(90%),在BJAB细胞中降低了70-80%。脂质组学分析显示,在PBL SKI-II中,神经酰胺水平升高,而在BJAB细胞中,ceranib-2则神经酰胺水平升高。 SKI-II处理可降低PBL和BJAB细胞中的鞘氨醇-1-磷酸(S1P)水平。此外,我们发现淋巴细胞的MV感染引起S1P的短暂增加(0.5至6小时),这被SKI-II阻止。研究抑制剂对代谢(mTORC1)活性的影响,我们发现ceranib-2降低了PBL中p70 S6K的磷酸化,而ceranib-2和SKI-II抑制剂均降低了BJAB细胞中p70 S6K的磷酸化。 。由于有效的MV复制需要mTORC1活性,因此抑制剂的这种作用是一种可能的抗病毒机制。另外,减少的细胞内S1P水平影响许多信号传导途径和功能,包括Hsp90活性,据报道这是MV复制所必需的。因此,我们发现用抑制剂17-AAG对Hsp90的药理学抑制作用强烈削弱了原发性PBL中的MV复制。因此,我们的数据表明,用酸性神经酰胺酶和鞘氨醇激酶抑制剂对淋巴细胞进行处理会通过影响包括mTORC1和Hsp90在内的许多细胞活性来损害MV复制,这会改变细胞的代谢状态,从而导致病毒的敌对环境。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号